139 related articles for article (PubMed ID: 35948444)
1. Combination Olaparib and Temozolomide for the Treatment of Glioma: A Retrospective Case Series.
Schaff LR; Kushnirsky M; Lin AL; Nandakumar S; Grommes C; Miller AM; Gavrilovic IT; Nolan C; Pentsova E; Mellinghoff IK; Kaley TJ
Neurology; 2022 Oct; 99(17):750-755. PubMed ID: 35948444
[TBL] [Abstract][Full Text] [Related]
2. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
3. Rechallenge temozolomide in glioma: A case series from India.
Patil VM; Tonse R; Kothari R; Chandrasekaran A; Pande N; Epari S; Gupta T; Jalali R
Indian J Cancer; 2017; 54(1):368-371. PubMed ID: 29199725
[TBL] [Abstract][Full Text] [Related]
4. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Everaert E; Neyns B; Joosens E; Strauven T; Branle F; Menten J
J Neurooncol; 2004 Oct; 70(1):37-48. PubMed ID: 15527106
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Chamberlain MC
Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
[TBL] [Abstract][Full Text] [Related]
8. PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Beppu T; Iwaya T; Sato Y; Nomura JI; Terasaki K; Sasaki T; Yamada N; Fujiwara S; Sugai T; Ogasawara K
Clin Nucl Med; 2022 Jul; 47(7):569-574. PubMed ID: 35452002
[TBL] [Abstract][Full Text] [Related]
9. Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
Zhou Z; Howard TA; Villano JL
Cancer Chemother Pharmacol; 2017 Nov; 80(5):1043-1046. PubMed ID: 28791452
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Kim YH; Park CK; Cho WH; Kim IA; Moon S; Choe G; Park SH; Kim IH; Kim DG; Jung HW; Lee MM; Bae SH; Cha SH; Kim CY
J Neurooncol; 2011 Jul; 103(3):503-12. PubMed ID: 20862518
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
Reyes-Botero G; Laigle-Donadey F; Mokhtari K; Martin-Duverneuil N; Delattre JY
J Neurooncol; 2014 Dec; 120(3):581-6. PubMed ID: 25139026
[TBL] [Abstract][Full Text] [Related]
12. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Taal W; Segers-van Rijn JM; Kros JM; van Heuvel I; van der Rijt CC; Bromberg JE; Sillevis Smitt PA; van den Bent MJ
J Neurooncol; 2012 May; 108(1):195-200. PubMed ID: 22396071
[TBL] [Abstract][Full Text] [Related]
13. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
[TBL] [Abstract][Full Text] [Related]
14. Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
Garcia CR; Slone SA; Morgan RM; Gruber L; Kumar SS; Lightner DD; Villano JL
Med Oncol; 2018 Aug; 35(10):136. PubMed ID: 30155806
[TBL] [Abstract][Full Text] [Related]
15. Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Yao H; Liu J; Zhang C; Shao Y; Li X; Feng M; Wang X; Gan W; Zhou Y; Huang Y
J Clin Neurosci; 2021 Aug; 90():82-88. PubMed ID: 34275586
[TBL] [Abstract][Full Text] [Related]
16. Salvage temozolomide for prior temozolomide responders.
Franceschi E; Omuro AM; Lassman AB; Demopoulos A; Nolan C; Abrey LE
Cancer; 2005 Dec; 104(11):2473-6. PubMed ID: 16270316
[TBL] [Abstract][Full Text] [Related]
17. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Minniti G; Scaringi C; De Sanctis V; Lanzetta G; Falco T; Di Stefano D; Esposito V; Enrici RM
J Neurooncol; 2013 Jan; 111(2):187-94. PubMed ID: 23129347
[TBL] [Abstract][Full Text] [Related]
19. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Sun X; Turcan S
Cells; 2021 May; 10(5):. PubMed ID: 34067729
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Yu Y; Villanueva-Meyer J; Grimmer MR; Hilz S; Solomon DA; Choi S; Wahl M; Mazor T; Hong C; Shai A; Phillips JJ; Wainer BH; McDermott M; Haas-Kogan D; Taylor JW; Butowski N; Clarke JL; Berger MS; Molinaro AM; Chang SM; Costello JF; Oberheim Bush NA
Neuro Oncol; 2021 Nov; 23(11):1872-1884. PubMed ID: 33823014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]